Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.35 |
| ▸ | AGER | Q15109 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244072 | 0.90 | AGER (0.41) | OPRM1TMEM97AGERMTNR1A | |
| SCHEMBL7244965 | 0.90 | AGER (0.41) | OPRM1TMEM97AGERMTNR1A | |
| SCHEMBL7244963 | 0.90 | AGER (0.41) | OPRM1TMEM97AGERMTNR1A | |
| SCHEMBL7247166 | 0.90 | HTR6 (0.38) | P2RX3P2RX2MTNR1A | |
| SCHEMBL7249524 | 0.90 | HTR6 (0.38) | P2RX3P2RX2MTNR1A | |
| SCHEMBL7247168 | 0.90 | HTR6 (0.38) | P2RX3P2RX2MTNR1A | |
| SCHEMBL7249818 | 0.88 | ALDH1A1 (0.37) | P2RX3P2RX2 | |
| SCHEMBL7250169 | 0.86 | HCRTR1 (0.42) | LTB4RLTB4R2MEN1KMT2AP2RX3 | |
| SCHEMBL7243374 | 0.85 | OPRD1 (0.47) | OPRM1SIGMAR1 | |
| SCHEMBL7241693 | 0.85 | ALDH1A1 (0.40) | OPRM1SIGMAR1P2RX3P2RX2AGER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | OPRM1 1237/4885LTB4R 3845/4885LTB4R2 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.